| Q58766089 | Absorption of Saponins by Coexisting Polysaccharides Alleviates Gut Microbial Dysbiosis with Dextran Sulfate Sodium-Induced Colitis in Model Mice |
| Q43515258 | Adalimumab for maintenance therapy for one year in Crohn's disease: results of a Latin American single-center observational study. |
| Q92619703 | Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome |
| Q37862584 | An evidence-based systematic review on medical therapies for inflammatory bowel disease |
| Q46505698 | Anti-Inflammatory and Anti-Oxidant Effects of p-Chloro-phenyl-selenoesterol on TNBS-Induced Inflammatory Bowel Disease in Mice. |
| Q27006589 | Association among genetic predisposition, gut microbiota, and host immune response in the etiopathogenesis of inflammatory bowel disease |
| Q30244767 | Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection |
| Q37292875 | Clinical and Sociodemographic Aspects of Inflammatory Bowel Disease Patients |
| Q40065810 | Crohn's disease environmental factors in the developing world: A case-control study in a statewide catchment area in Brazil |
| Q24198106 | Curcumin for maintenance of remission in ulcerative colitis |
| Q24239821 | Curcumin for maintenance of remission in ulcerative colitis |
| Q38845478 | Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico. |
| Q92967397 | Epidemiology of inflammatory bowel disease in Mexico and Colombia: Analysis of health databases, mathematical modelling and a case-series study |
| Q92306857 | Epidemiology of inflammatory bowel disease in South America: A systematic review |
| Q33948374 | Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis |
| Q39238748 | Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China |
| Q42695145 | Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology |
| Q50525563 | Impact of biological therapy on body composition of patients with Chron's disease. |
| Q91655612 | Incidence and prevalence of inflammatory bowel disease in Mexico from a nationwide cohort study in a period of 15 years (2000-2017) |
| Q44431010 | Incidence of inflammatory bowel disease in the health area of Navalmoral de la Mata (Caceres, Spain) between 2000 and 2009 |
| Q22250934 | Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review |
| Q89219089 | Inflammatory Bowel Disease in Latin America: A Systematic Review |
| Q59126044 | Inflammatory bowel disease epidemiology in São Paulo State, Brazil |
| Q35012080 | Inflammatory bowel disease in an underdeveloped region of Northeastern Brazil |
| Q24658457 | Inflammatory bowel disease: A descriptive study of 716 local Chilean patients |
| Q26769891 | Inflammatory bowel disease: can omega-3 fatty acids really help? |
| Q92861781 | Inflammatory bowel diseases: time of diagnosis, environmental factors, clinical course, and management - a follow-up study in a private inflammatory bowel disease center (2003-2017) |
| Q37577712 | Making sense of the cause of Crohn's - a new look at an old disease |
| Q51252824 | Nutritional intake according to injury extent in ulcerative colitis patients. |
| Q34288932 | Race and inflammatory bowel disease in an urban healthcare system |
| Q44675776 | Research in inflammatory bowel diseases in Latin America: a challenge ahead. |
| Q97644842 | Review of the epidemiology and burden of ulcerative colitis in Latin America |
| Q37528116 | Systematic review: The role of race and socioeconomic factors on IBD healthcare delivery and effectiveness |
| Q36174140 | The Demographic and Clinical Characteristics of Ulcerative Colitis in a Northeast Brazilian Population |
| Q91789206 | The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology |
| Q64112806 | The Use of Probiotic Therapy to Modulate the Gut Microbiota and Dendritic Cell Responses in Inflammatory Bowel Diseases |
| Q100504047 | The four epidemiological stages in the global evolution of inflammatory bowel disease |
| Q38577572 | The global burden of IBD: from 2015 to 2025. |
| Q55426068 | The prevalence and phenotype in Brazilian patients with inflammatory bowel disease. |
| Q88899916 | Ulcerative colitis |
| Q22242718 | Where are we on worms? |
| Q112617227 | Xianglian Pill Suppresses Inflammation and Protects Intestinal Epithelial Barrier by Promoting Autophagy in DSS Induced Ulcerative Colitis Mice |